Physician profile
Jovan Wright
NPI 1922820497
$1,932.59
in general payments reported to CMS, 2019-2025
14 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $52.02 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $748.49 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $315.45 | 2025 | |
| Novo Nordisk INC | $233.27 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.31 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $119.11 | 2025 | |
| Amgen INC. | $114.02 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $59.18 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $48.08 | 2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $35.10 | 2025 | |
| Astellas Pharma US INC | $24.92 | 2025 | Veozah |
| Hologic Sales and Service, LLC | $23.77 | 2025 | Thinprep 2000 Processor, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.57 | 2025 | Jardiance |
| Pfizer INC. | $17.01 | 2025 | |
| Merck Sharp & Dohme LLC | $14.31 | 2025 | Enflonsia, Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jovan Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.